Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis.
Because the value of usual immune globulin preparations in preventing Type B hepatitis is doubtful, we carried out a double-blind comparison of a control human immune globulin preparation with one--identified as HBIG--that had a high concentration (442 mug per milliliter) of antibodies to surface components of hepatitis B virus. Effectiveness was tested in spouses of patients with acute Type B hepatitis. Within 150 days after injection, nine of 33 spouses in the control group had symptomatic Type B hepatitis, compared with one of 25 spouses receiving HBIG. One non-B case also occurred in the HBIG group. Five control globulin recipients had evidence of subclinical hepatitis B infection, compared with one HBIG recipient.  Thus, HBIG appeared effective in suppressing not only disease, but also infection itself. Prophylactic value has been demonstrated in persons who should now be recognized as being at exceptionally high risk.
D000208:Acute Disease; D000906:Antibodies; D002986:Clinical Trials as Topic; D005260:Female; D006506:Hepatitis A / Q000453:epidemiology; D006509:Hepatitis B / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000008:administration & dosage / Q000032:analysis; D006511:Hepatitis B Antigens / Q000032:analysis; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male
D000906:Antibodies; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D007136:Immunoglobulins